SCHEMBL30089263

SCHEMBL30089263

Cn1ccc2ccc(C#N)cc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.49
CDC7 O00311 7/20 0.48
CDK2 P24941 5/20 0.48
MAP3K14 Q99558 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.43
KDM4E B2RXH2 5/20 0.41
ALDH1A1 P00352 5/20 0.41
TSHR P16473 3/20 0.41
HSD17B10 Q99714 3/20 0.41
HPGD P15428 2/20 0.41
GLA P06280 2/20 0.41
HTT P42858 1/20 0.41
USP2 O75604 1/20 0.40
POLB P06746 1/20 0.40
PRKCI P41743 1/20 0.40
CCNE2 O96020 1/20 0.40
CDK4 P11802 1/20 0.40
CCND1 P24385 1/20 0.40
CCNE1 P24864 1/20 0.40
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL506374 1.00 CYP2A6 (0.49) CYP2A6CDC7CDK2MAP3K14L3MBTL1
SCHEMBL1779268 0.85 PRKCI (0.53) CYP2A6CDC7KDM4EALDH1A1GLA
SCHEMBL29499059 0.85 PRKCI (0.53) CYP2A6CDC7KDM4EALDH1A1GLA
SCHEMBL18029368 0.81 HTR7 (0.49) CYP2A6CDC7CDK2MAP3K14L3MBTL1
Bromide SCHEMBL7491178 0.79 KDM4E (0.37) CYP2A6CDC7CDK2MAP3K14KDM4E
SCHEMBL8430662 0.78 ALDH1A1 (0.48) CDC7CDK2MAP3K14KDM4EALDH1A1
SCHEMBL8253236 0.77 CDC7 (0.50) CDC7CDK2MAP3K14KDM4EALDH1A1
SCHEMBL27924593 0.77 CDC7 (0.48) CDC7CDK2MAP3K14KDM4EALDH1A1
SCHEMBL20655577 0.77 CDC7 (0.44) CYP2A6CDC7CDK2MAP3K14KDM4E
SCHEMBL20656047 0.77 ALDH1A1 (0.50) CYP2A6CDC7CDK2MAP3K14KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115974845-B Preparation method of Ornitinib intermediate 奥锐特药业股份有限公司 2024-09-20 CN disclosed
US-11958850-B2 Heteroaryl compounds for kinase inhibition TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-04-16 US disclosed
US-20230102829-A1 Heteroaryl Compounds For Kinase Inhibition ARIAD PHARMACEUTICALS, INC. 2023-03-30 US disclosed
CN-113004187-B Compound with function of inhibiting activity of organic anion transporter 1, preparation method and application 沈阳药科大学 2022-09-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11958850-B2 Heteroaryl compounds for kinase inhibition ERBB2, EGFR, ERBB3 CYP2A6 2373/4885CDC7 380/4885CDK2 53/4885
US-20230102829-A1 Heteroaryl Compounds For Kinase Inhibition ERBB2, EGFR, ERBB3 CYP2A6 2373/4885CDC7 380/4885CDK2 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.